<div class="box02 st01"> <p class="tit03 mt0">Collaboration Opportunities for R&D Co-works</p> <p class="txt03">Currently not interested in meetings with CRO''s or other service providers.</p> <p class="tit03">Collaboration Opportunities for In-Licensing</p> <p class="tit01 ml10">What Lundbeck is looking for</p> <p class="txt03">Lundbeck is looking for projects and products that can strengthen our position as a leading global CNS company. Our strategy is to achieve this by actively supplementing our internal development with external opportunities.</p> <p class="tit01 ml10">Therapeutic areas</p> <p class="txt03">Our primary licensing interest is in projects and products that expand our range of pharmaceuticals for the treatment of all disorders within CNS - including orphan indications.</p> <ul class="list02"> <li>Psychiatry: mood disorders, anxiety disorders, psychotic disorders, personality disorders, addiction, development disorders, eating disorders, etc.</li> <li>Neurology: movement disorders, dementias, cerebrovascular(e.g. stroke), demyelinating disorders (e.g. multiple sclerosis), sleep disorders, traumatic injuries, pain, epilepsies, etc.</li> </ul> <p class="tit01 ml10">Stages</p> <p class="txt03">As a fully integrated pharmaceutical company, Lundbeck is active across all stages of a product’s development. Lundbeck is therefore interested in products at all stages:</p> <ul class="list02"> <li>Pre-clinical projects</li> <li>Early-stage development projects</li> <li>Late-stage development projects</li> <li>Registered or marketed products</li> </ul> <p class="txt03">In order to develop new ground-breaking therapies, Lundbeck is always interested in expanding our R&D capabilities by establishing research and development agreements with external parties.</p> <p class="tit01 ml10">Types of partnerships</p> <p class="txt03">Lundbeck is currently engaged in all types of partnering agreements and is therefore interested in:</p> <ul class="list02"> <li>In-licensing opportunities</li> <li>Out-licensing opportunities</li> <li>Co-development</li> <li>Co-promotion, cross-promotion and co-marketing agreements</li> <li>Strategic alliances</li> <li>Joint ventures</li> </ul> <p class="tit01 ml10">Territories</p> <p class="txt03">By being an EU-founded company, Lundbeck has historically had an interest in European rights for products due to our European strength and focus. We are, however, expanding our business in all markets including the US, South America, and Asia.</p> <p class="txt03">Geographically we are focused on expanding our presence in all markets and are preferably interested in global or regional partnerships, however partnerships at a country level may also be of interest.</p> <p class="tit03">Collaboration Opportunities for Out-Licensing</p> <p class="txt03">Currently Lundbeck has one product available for out-licensing:</p> <p class="txt03">1. Phase II ready compound for Parkinson’s disease (global opportunity) Lundbeck is currently seeking global partner for a phase II ready D1/D2 agonist prodrugs (Lu 02-750 and Lu AE04621) for Parkinson’s disease.</p> <p class="txt03">Lu 02-750 and Lu AE04621 are orally bioavailable prodrugs to the pharmacologically active catecholamine Lu AA40326. Lu AA40326 is a long-acting compound in vivo with efficacy on par with L-DOPA or apomorphine. Lu 02-750 and Lu AE04621 may show the following benefits, compared to existing dopamine replacement therapies available to patients with Parkinson’s disease:</p> <ul class="list02"> <li>Efficacy as good as L-DOPA with much improved potency</li> <li>Less dyskinesia vs. L-DOPA</li> <li>Improved duration of action vs. L-DOPA/apomorphine</li> <li>Oral route of administration over apomorphine</li> </ul> <p class="txt03">Based on the above expected benefits, Lundbeck expects a great potential for the new treatment for both early and advanced Parkinson’s patients.</p> </div>
소스입니다. Ctrl+C를 눌러 클립보드로 복사하세요

닫기